


CLAIMS

1. A therapeutic and/or preventive agent for pulmonary disease that exhibits neutrophilic inflammation, which comprises 7-[2-(3,5-dichloro-4-pyridyl)-1-oxoethyl]-4-methoxy-spiro[1,3-benzodioxol-2,1'-cyclopentane] represented by formula (I)



(I)


or a pharmaceutically acceptable salt thereof as an active ingredient.

2. The therapeutic and/or preventive agent for pulmonary disease that exhibits neutrophilic inflammation according to Claim 1, wherein the pulmonary disease that exhibits neutrophilic inflammation is a disease selected from the group consisting of chronic obstructive pulmonary disease (COPD), pulmonary emphysema and chronic bronchitis.

3. The therapeutic and/or preventive agent for pulmonary disease that exhibits neutrophilic inflammation according to Claim 1, wherein the pulmonary disease that exhibits neutrophilic inflammation is acute respiratory distress

syndrome (ARDS) or acute lung injury (ALI).

4. A method for treating and/or preventing pulmonary disease that exhibits neutrophilic inflammation, which comprises administering an effective amount of 7-[2-(3,5-dichloro-4-pyridyl)-1-oxoethyl]-4-methoxy-spiro[1,3-benzodioxol-2,1'-cyclopentane] represented by formula (I)




(I)

or a pharmaceutically acceptable salt thereof.

5. The method for treating and/or preventing pulmonary disease according to Claim 4, wherein the pulmonary disease that exhibits neutrophilic inflammation is a disease selected from the group consisting of COPD, pulmonary emphysema and chronic bronchitis.

6. The method for treating and/or preventing pulmonary disease according to Claim 4, wherein the pulmonary disease that exhibits neutrophilic inflammation is ARDS or ALI.

7. Use of 7-[2-(3,5-dichloro-4-pyridyl)-1-oxoethyl]-4-methoxy-spiro[1,3-benzodioxol-2,1'-cyclopentane] represented by formula (I)



( I )

or a pharmaceutically acceptable salt thereof, for the manufacture of a therapeutic and/or preventive agent for pulmonary disease that exhibits neutrophilic inflammation.

8. Use of 7-[2-(3,5-dichloro-4-pyridyl)-1-oxoethyl]-4-methoxy-spiro[1,3-benzodioxol-2,1'-cyclopentane] or a pharmaceutically acceptable salt thereof according to Claim 7, wherein the pulmonary disease that exhibits neutrophilic inflammation is a disease selected from the group consisting of COPD, pulmonary emphysema and chronic bronchitis.

9. Use of 7-[2-(3,5-dichloro-4-pyridyl)-1-oxoethyl]-4-methoxy-spiro[1,3-benzodioxol-2,1'-cyclopentane] or a pharmaceutically acceptable salt thereof according to Claim 7, wherein the pulmonary disease that exhibits neutrophilic inflammation is ARDS or ALI.